If you are a provider looking to refer a patient to our program, please complete our referral form.

If your patient is eligible, we contact them to discuss details about the transplant process and to schedule an evaluation. Once we complete the evaluation, we inform you of your patient’s test results and give you our recommendations regarding their suitability for transplant.

Our kidney/pancreas transplant team performs hundreds of transplants per year. We ensure every patient receives highly coordinated, personalized care.

Kidney/pancreas transplant referral form

We have decades of experience providing comprehensive liver care to patients before, during and after liver transplant. Our liver transplant program is part of the gastroenterology and GI surgery program nationally ranked by U.S. News & World Report.

Liver transplant referral form

Our heart transplant program is part of the cardiology and heart surgery program nationally ranked by U.S. News & World Report. We’ve performed over 1,000 successful heart transplants, giving us premiere expertise and experience.

Heart transplant referral form

Our transplant program has performed over 2,000 lung transplant surgeries, gathering worldwide recognition. Lung transplant evaluation can be intensive and complex. Our guidelines for referral include:

• At the time of diagnosis of IPF/UIP based on a biopsy or CT scan findings

• Any form of fibrosis with FVC < 80% predicted or DLCO < 40% predicted

• Decline in FVC ≥ 10% over the past 2 years

• Decline in DLCO ≥ 15% over the past 2 years

• Need for supplemental oxygen at rest or with exertion

• FEV1 below 30% predicted or a rapid decline in FEV1 

• Exacerbation of pulmonary disease requiring ICU stay

• Increasing frequency of exacerbations requiring antibiotic therapy

• Refractory and/or recurrent pneumothorax

• Recurrent hemoptysis not controlled by embolization

• Any form of fibrosis with FVC < 80% predicted or DLCO < 40% predicted

• Decline in FVC ≥ 10% over the past 2 years

• Decline in DLCO ≥ 15% over the past 2 years

• Need for supplemental oxygen at rest or with exertion

• BODE score 5-6

• Frequent acute exacerbations

• Increase in BODE score > 1 over 24 months

• FEV1 in the range of 20-25% predicted

• Pulmonary artery to aorta diameter > 1 on CT scan

• NYHA functional class III or IV, irrespective of ongoing therapy

• ESC/ERS intermediate or high risk, or REVEAL risk score 8 despite appropriate therapy

• Significant RV dysfunction despite appropriate PAH therapy

• Need for IV or SC prostacyclin therapy

• Progressive disease despite appropriate therapy or hospitalization for PAH symptoms

• Known or suspected high-risk variants such as PVOD or scleroderma

• Signs of secondary liver or kidney dysfunction due to PAH

• Recurrent hemoptysis

• Patients must be free from all nicotine product usage for at least six months (including e-cigarettes, vapor cigarettes, chew, gum, patches, etc.)

• Acceptable weight status, usually BMI < 35 kg/m2

Lung transplant referral form